Breath test to measure muscle sensitivity in young and older adults
The Efficacy of a Non-Invasive 13CO2 'Breath Test' to Detect Anabolic Resistance Following Step Reduction in Younger and Older Adults
NA · University of Toronto · NCT05216809
This study is testing a breath test to see how aging and changes in activity levels affect how well young and older adults respond to protein and exercise.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 32 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University of Toronto (other) |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT05216809 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of a non-invasive 13CO2 breath test to evaluate differences in anabolic sensitivity between young and older adults after periods of habitual and reduced physical activity. Participants will undergo a series of sessions, including an introductory video call and body composition assessments, to gather data on their physical activity levels and body composition. The focus is on understanding how aging and changes in activity levels affect the body's response to dietary protein and exercise. The study aims to provide insights into anabolic resistance, which is a common issue in older adults.
Who should consider this trial
Good fit: Ideal candidates are healthy young adults aged 18-35 and older adults aged 60-80 who are physically active with a daily step count greater than 7,000.
Not a fit: Patients with chronic illnesses, recent cancer, or those using certain medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for enhancing muscle health and preventing sarcopenia in older adults.
How similar studies have performed: While the specific use of a 13CO2 breath test is novel, related studies on anabolic sensitivity and aging have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy young (age: 18-35 years) or older (age: 60-80 years) adults * Average daily step-count \>7,000/day * BMI between normal to overweight (18.5-29.9 kg/m2) Exclusion Criteria: * Regular use of nonsteroidal anti-inflammatory drugs (with the exception of daily low-dose aspirin) * Use of anticoagulants * Use of a walker, cane, or assistive walking device * Current or recently remised cancer * Infectious or gastrointestinal disease * Inability to comply with study protocol (e.g., \>2,000 steps/day during Step-Reduction Phase) * Regular tobacco use * Self-reported illicit drug use (e.g. growth hormone, testosterone, etc.) * Diagnosed chronic illness (e.g. type 2 diabetes, heart disease, thyroid disease) * Pregnant * Hormonal Replacement Therapy
Where this trial is running
Toronto, Ontario
- Goldring Centre for High Performance Sport at the University of Toronto — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Principal investigator: Daniel Moore, PhD — University of Toronto
- Study coordinator: Daniel R Moore, PhD
- Email: dr.moore@utoronto.ca
- Phone: 4169464088
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sedentary Behavior, Aging, Sarcopenia, Amino Acids, Dietary Protein, Skeletal Muscle, Step-Reduction, Anabolic Resistance